Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment

Area of Science:

• Endocrinology
• Sexual Medicine
• Addiction Psychiatry

Background:

• Opioid/opioid use is linked to sexual dysfunction, including low libido and erectile issues.
• Understanding sexual dysfunction in men undergoing opioid replacement therapy (ORT) is crucial for comprehensive patient care.

Purpose of the Study:

• To determine the prevalence of sexual dysfunction in men receiving methadone maintenance treatment (MMT) or buprenorphine maintenance treatment (BMT).
• To investigate the underlying causes of sexual dysfunction in these patient populations.

Main Methods:

• 103 men on MMT (N=84) or BMT (N=19) were assessed.
• Evaluations included the International Index of Erectile Function (IIEF), hormone assays, Beck Depression Inventory, BMI, and substance use history.
• Partnered men on MMT were compared to reference groups and men on BMT.

Main Results:

• Men on MMT showed significantly lower mean IIEF scores compared to reference groups and men on BMT.
• 53% of partnered men on MMT reported erectile dysfunction (ED), compared to 24% in reference groups.
• Lower total testosterone and depression were associated with reduced erectile function (EF) and IIEF scores in MMT patients.

Conclusions:

• Men on MMT exhibit a high prevalence of ED, associated with hypogonadism and depression.
• Practitioners should screen for sexual dysfunction in men undergoing opioid replacement therapy.
• Future research should explore dose reduction, androgen replacement, and depression treatment for sexual dysfunction in opioid-treated men.